Unicycive Therapeutics, Inc. Operating Income Loss

• Unicycive Therapeutics, Inc. showed an increase of +8.1% in Operating Income Loss from 2024 to 2025.
• This data is from Unicycive Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
• XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 6 years of available data (2020 to 2025), Unicycive Therapeutics, Inc.'s Operating Income Loss has declined by 1,361.2%.
• Historical annual values: Fiscal year 2025: -$29.52 million | Fiscal year 2024: -$32.12 million | Fiscal year 2023: -$20.77 million | Fiscal year 2022: -$18.05 million | Fiscal year 2021: -$8.98 million | Fiscal year 2020: -$2.02 million.
• Data sourced from SEC EDGAR public filings as of June 22, 2026.

Last verified: June 22, 2026